gilead sciences inc (GILD:NASDAQ GS)

Executive Profile*

Background*

Dr. Richard J. Whitley, Rich, M.D., Ph.D. serves as an Advisor of Vaxart, Inc. Dr. Whitley serves as Divisional Director of Pediatric Infectious Diseases, Vice Chairman of Department of Pediatrics, Senior Scientist of Department of Gene Therapy, Senior Scientist of Cancer Research and Training Center, Associate Director for Clinical Studies of Center for AIDS Research, Director of Center for Biodefense and Emerging Infections at The University of Alabama at Birmingham. ... He manages a large clinical trials program funded by the NIH. He is an Advisor to the NIH and FDA. He is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. His work has made fundamental contribution towards understanding and treatment of Herpes Simplex viral infections. He is also an Advisor to the Infectious Diseases Society of America and a member of advisory bodies at the National Institute of Health and the U.S. Food and Drug Administration. He has been a Director of Gilead Sciences Inc. since July 2008 and Gilead Palo Alto, Inc since 2008. He serves as a Member of Scientific Advisory Board of 3-V Biosciences, Inc. He serves as a Director of Primus Pharmaceuticals, Inc. He serves as a Member of Influenza Advisory Board at Adamas Pharmaceuticals, Inc. He serves as a Member of Scientific Advisory Board and Independent Health Policy Advisory Board at Gilead Sciences Inc. He has been a Member of Clinical Advisory Board at NexBio, Inc. since April 2009. He serves as a Member of Scientific Advisory Board at Juvaris BioTherapeutics, Inc., Nurel Therapeutics, Inc., Vaxin Inc., Aviron & Integrated Nano-Technologies LLC, Arrow Therapeutics Ltd., Microbiotix, Inc., Apath, LLC and of ImQuest Pharmaceuticals, Inc. He has been Member of Scientific & Medical Advisory Board at Inhibitex, Inc., since November 2007. He serves as Member of Advisory Board at Intelligent Medical Devices Inc. He serves as Scientific & Strategic Advisor at Janus Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board and Clinical Advisory Board at Achillion Pharmaceuticals, Inc. Dr. Whitley served as Member of the Overseas Advisory Board of aRigen Pharmaceuticals, Inc. (also knowna as Arigen, Inc.) He served as Member of Scientific & Medical Advisory Board of Diamyd Medical AB since 2006. Dr. Whitley served as Director of Fermavir Pharmaceuticals, Inc. and Venus Beauty Supply Inc. since August 16, 2005. He served as a Member of Scientific Advisory Board of Genelabs Technologies Inc., Chimerix, Inc. and Epiphany Biosciences, Inc. He served as a Member of the Scientific Advisory Council of MediGene AG. Dr. Whitley's other research interest is in the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy and engineering of herpes simplex virus for gene therapy. He served as President of the International Society of Antiviral Research. Dr. Whitley is an Editor of Antiviral Research, and is a member of the Editorial Boards of the Jounal of Infectious Diseases, Sexually Transmitted Diseases, Reviews in Medical Virology, Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Infectious Diseases Watch for Pediatricians, Seminars in Pediatric Infectious Diseases, Gene Therapy, and Medscape Infectious Disease. He has won several awards for his work. Dr. Whitley has been elected to the Infectious Diseases Society of America, Fellow, American Society of Microbiology, American Society of Clinical Investigation and Association of American Physicians. He is a Professor of Pediatrics, Microbiology and Medicine at the University of Alabama in Birmingham, and holds the Loeb Eminent Scholar Chair in Pediatrics. Dr. Whitley graduated from George Washington University School of Medicine with an MD and from Duke University with a BS in Chemistry. He holds B.A in chemistry from Duke University.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
GILD:US	$55.93 USD	+0.45

COMPETITOR COMPENSATION